GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

GeoVax Labs, Inc. (NasdaqCM: GOVX) will participate in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. Chairman and CEO David Dodd is set to present, with an on-demand listening option starting at 7:00 AM ET on March 9. The presentation will be available for 90 days. Investors can schedule virtual one-on-one meetings with Mr. Dodd during the conference. GeoVax is focused on developing vaccines for infectious diseases and cancer, including COVID-19 and HIV, utilizing an innovative vaccine platform.

Virtual Conference to be Held March 9-10, 2021

ATLANTA, GA, March 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, announced today that Chairman, President, and CEO David Dodd will present at the H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.

The presentation will be available for on-demand listening beginning at 7:00 AM ET on Tuesday, March 9, 2021 and will be available for 90 days.  For those interested in viewing Mr. Dodd’s presentation, conference registration can be accessed here.  Mr. Dodd will be available for virtual one-on-one meetings with investors on March 9-10, and meeting requests can be made on the conference website once an investor is registered.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens in the person receiving the vaccine. The production of VLPs in the person being vaccinated can mimic virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.

GeoVax’s current development programs are focused on preventive vaccines against COVID-19, HIV, Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines against multiple cancers. The Company has designed a preventive HIV vaccine candidate to fight against the subtype of HIV prevalent in the commercial markets of the Americas, Western Europe, Japan, and Australia; human clinical trials for this program are managed by the HIV Vaccine Trials Network (HVTN) with the support of the National Institutes of Health (NIH). GeoVax’s HIV vaccine is also part of two separate collaborative efforts to apply its innovative gene therapy approach toward a functional cure for HIV.

Contact:

GeoVax Labs, Inc.

investor@geovax.com

678-384-7220

FAQ

When is GeoVax presenting at the H.C. Wainwright Global Life Sciences Conference?

GeoVax will present at the conference on March 9-10, 2021.

How can I view GeoVax's presentation at the conference?

The presentation will be available for on-demand listening starting at 7:00 AM ET on March 9, 2021, and will remain accessible for 90 days.

Who will be presenting on behalf of GeoVax at the conference?

Chairman, President, and CEO David Dodd will represent GeoVax at the conference.

What is the focus of GeoVax's vaccine development?

GeoVax is developing vaccines for infectious diseases and cancer, including COVID-19, HIV, Zika Virus, and multiple cancers.

Can investors meet with GeoVax's CEO during the conference?

Yes, investors can schedule virtual one-on-one meetings with CEO David Dodd on March 9-10, 2021.